Accord Biopharma
Focus: Accord Biopharma is a public specialty pharmaceutical company headquartered in Raleigh, NC, focused on biosimilars and specialty pharma across oncology, cardiovascular, neurology, immunology, and hematology. The company is heavily dependent on a single product generating 99% of revenue.
Profile data last refreshed 57m ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
5
Should You Work at Accord Biopharma?
AI assessmentAccord Biopharma is a high-risk, low-growth specialty pharma play suitable only for risk-tolerant commercial or operations professionals seeking stability in a single-product cash cow, not for scientists or those seeking career advancement.
Why Work Here
- Established public company with diversified therapeutic area exposure (oncology, cardiovascular, neurology, immunology, hematology) across multiple product types
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$262M Part DDeclining
Post-LOE
Anchor product generating 99% of company revenue; post-LOE status indicates ongoing generic erosion and mature market position.
Help build intelligence for Accord Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.